Morgan Stanley released a report stating that Akeso's (09926.HK) Ivoxi HARMONi-2 data exceeded expectations and met the "most bullish" scenario prediction for the stock. Due to Ivoxi's strong data and consistency in safety, the company's revenue model has been adjusted to reflect overseas revenue contribution, raising the target price from HK$64 to HK$78, while maintaining a "shareholding" rating.

Morgan Stanley has lowered its loss forecast for Akeso this year by 30%, and decreased next year's loss forecast by 17%, while raising the profit forecast for 2026 by 13%.